RxDoctor Payments Data

Rex Heaton, NP

Family · Saint George, UTNPI 1477627917

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 806 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,891in general payments, 2019–2025

Across 806 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Merck$1K
  • Johnson & Johnson$963
  • Pfizer$824
  • Astellas Pharma US Inc$728
  • Seagen Inc.$674
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$14,98094%
  • Education$9106%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)76$1,653
Merck48$1,037
Johnson & Johnson(2 entities)51$963
Pfizer61$824
Astellas Pharma US Inc22$728
Seagen Inc.40$674
Sanofi22$599
Daiichi Sankyo Inc.32$594
Novartis23$518
E.r. Squibb & Sons, L.L.C.29$517
Eisai Inc.28$489
Genentech USA, Inc.21$481
Lilly USA, LLC25$446
Amgen29$432
Incyte Corporation23$424
AbbVie19$375
Pharmacyclics LLC, An Abbvie Company16$353
Dendreon Pharmaceuticals LLC11$344
Bristol Myers Squibb22$339
GSK16$335
Gilead(2 entities)14$287
EMD Serono, Inc.14$262
Bayer14$251
Boehringer Ingelheim10$226
Regeneron Healthcare Solutions, Inc.8$167
Myovant Sciences Inc.11$165
Sobi, Inc7$158
Array Biopharma Inc10$133
Takeda Pharmaceuticals U.S.A., Inc.5$132
Sumitomo Pharma America, Inc.6$131
Coherus Oncology, Inc.6$116
Genmab U.S., Inc.5$115
Beigene USA, Inc.5$111
Karyopharm Therapeutics Inc.5$102
Blueprint Medicines Corporation4$97
Jazz Pharmaceuticals Inc.6$95
Stemline Therapeutics Inc.5$94
AVEO Pharmaceuticals, Inc.2$89
Rigel Pharmaceuticals, Inc.4$68
Servier Pharmaceuticals LLC3$65
Geron Corporation3$64
Puma Biotechnology, Inc.3$57
Deciphera Pharmaceuticals Inc.3$56
Pharmaessentia USA Corporation3$55
Tersera Therapeutics LLC2$44
CTI Biopharma Corp.2$43
G1 Therapeutics, Inc.2$40
Celltrion USA Inc.1$37
Ipsen Biopharmaceuticals, Inc2$36
Agios Pharmaceuticals, Inc.2$35
CSL Behring2$34
Heron Therapeutics, Inc.2$33
Tolmar Pharmaceuticals, Inc.2$32
Recordati_rare_diseases_inc.1$31
Exelixis Inc.2$30
Acrotech Biopharma Inc.2$30
Morphosys, US Inc.2$28
Amneal Pharmaceuticals LLC1$25
Fennec Pharmaceuticals, Inc.1$23
Epizyme, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,891 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$783,726
Medicare patients
253
Services billed
42,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$47,108
XareltoRivaroxaban37$35,289
Anastrozole147$2,859
Hydroxyurea103$2,715
Anagrelide Hcl22$2,423
Letrozole47$1,898
Exemestane11$1,510
Potassium Chloride50$1,318
Oxycodone Hcl41$1,280
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen34$1,074
Allopurinol109$1,039
Dexamethasone18$955
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$902
Gabapentin56$861
Prochlorperazine Maleate16$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$824$47,10837 claims
Johnson & JohnsonXarelto$963$35,28937 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$12016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.

Other family in Saint George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →